Literature DB >> 24966972

Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.

Chunze Zhou1, Ruifeng Wang2, Yikun Ding1, Linan Du3, Changlong Hou1, Dong Lu1, Li Hao2, Weifu Lv1.   

Abstract

PURPOSE: Transarterial chemoembolization (TACE) is an effective treatment for patients with unresectable hepatocellular carcinoma (HCC). However, acute kidney injury (AKI) is a severe complication that commonly occurs in patients undergo TACE. In this study, we aim to investigate the incidence and risk factors associated with AKI in HCC patients received TACE treatment.
METHODS: This study enrolled 380 HCC patients who received a total of 453 TACE treatments. The incidence, clinical outcomes and risk factors of AKI were examined.
RESULTS: The incidence of post-TACE AKI was 9.05% (41/453). Of these, 3 patients (7.3%) progressed to chronic kidney failure while 7 patients (17.1%) died within 1 month of TACE. The Child-Pugh score (OR=3.784, 95% CI 1.899-7.542, p=0.000), pre-operative serum uric acid (OR=1.450, 95% CI 1.202-1.750, p=0.000), and proteinuria (OR=2.393, 95% CI 1.139-5.031, p=0.021) were independent risk factors for the development of post-TACE AKI.
CONCLUSION: AKI is a common complication in HCC patients received TACE. The Child-Pugh score, preoperative serum uric acid and proteinuria may be used to predict the risk of post-TACE AKI in HCC patients undergo TACE.

Entities:  

Keywords:  AKI; HCC; TACE; kidney failure; liver cancer

Mesh:

Substances:

Year:  2014        PMID: 24966972      PMCID: PMC4069907     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  35 in total

1.  Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule.

Authors:  Zhiying Zou; Brian Chung; Thao Nguyen; Sueann Mentone; Brent Thomson; Daniel Biemesderfer
Journal:  J Biol Chem       Date:  2004-06-04       Impact factor: 5.157

Review 2.  Structural and functional features of protein handling in the kidney proximal tubule.

Authors:  E I Christensen; S Nielsen
Journal:  Semin Nephrol       Date:  1991-07       Impact factor: 5.299

3.  In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies.

Authors:  Marina Morigi; Simona Buelli; Stefania Angioletti; Cristina Zanchi; Lorena Longaretti; Carla Zoja; Miriam Galbusera; Sara Gastoldi; Peter Mundel; Giuseppe Remuzzi; Ariela Benigni
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

4.  Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan.

Authors:  Kunitoshi Iseki; Kozen Kinjo; Chiho Iseki; Shuichi Takishita
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

5.  Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome.

Authors:  T-I Huo; J-C Wu; Y-H Huang; J-H Chiang; P-C Lee; F-Y Chang; S-D Lee
Journal:  Aliment Pharmacol Ther       Date:  2004-05-01       Impact factor: 8.171

6.  Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease.

Authors:  Eun-Sun Ryu; Mi Jin Kim; Hyun-Soo Shin; Yang-Hee Jang; Hack Sun Choi; Inho Jo; Richard J Johnson; Duk-Hee Kang
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-02

7.  Diuretics, mortality, and nonrecovery of renal function in acute renal failure.

Authors:  Ravindra L Mehta; Maria T Pascual; Sharon Soroko; Glenn M Chertow
Journal:  JAMA       Date:  2002-11-27       Impact factor: 56.272

8.  Renal function after cardiac surgery: adverse effect of furosemide.

Authors:  Raúl Lombardi; Alejandro Ferreiro; Cristina Servetto
Journal:  Ren Fail       Date:  2003-09       Impact factor: 2.606

9.  Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria.

Authors:  Ariela Benigni; Daniela Corna; Carla Zoja; Lorena Longaretti; Elena Gagliardini; Norberto Perico; Thomas M Coffman; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2004-10       Impact factor: 10.121

10.  Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study.

Authors:  Teh-Ia Huo; Jaw-Ching Wu; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  Liver Int       Date:  2004-06       Impact factor: 5.828

View more
  10 in total

1.  Expression of Girdin in primary hepatocellular carcinoma and its effect on cell proliferation and invasion.

Authors:  Ke Cao; Can Lu; Shuang Han; Qiong Zou; Jingjing Li; Dingfang Xie; Siqi He; Li Yu; Jianda Zhou; Xiaowei Peng; Peiguo Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma.

Authors:  Mari Aoe; Takafumi Kanemitsu; Takamasa Ohki; Satoru Kishi; Yoshiyasu Ogura; Yuto Takenaka; Toyohiro Hashiba; Hiroko Ambe; Emi Furukawa; Yu Kurata; Masahiro Ichikawa; Ken Ohara; Tomoko Honda; Satoshi Furuse; Katsunori Saito; Nobuo Toda; Naobumi Mise
Journal:  Clin Exp Nephrol       Date:  2019-06-10       Impact factor: 2.801

3.  Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study.

Authors:  Bo-Ching Lee; Kao-Lang Liu; Cheng-Li Lin; Chia-Hung Kao
Journal:  Eur Radiol       Date:  2017-06-07       Impact factor: 5.315

4.  Impact of low serum hemoglobin on development of contrast-induced nephropathy (CIN) in patients with hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE).

Authors:  Youjiao Si; Wenge Sun; Kaikai Zhao; Xianchuang Liu; Ke Ren
Journal:  Int Urol Nephrol       Date:  2021-01-04       Impact factor: 2.370

5.  Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Won Sohn; Cheol Bae Ham; Nam Hee Kim; Hong Joo Kim; Yong Kyun Cho; Woo Kyu Jeon; Byung Ik Kim
Journal:  PLoS One       Date:  2020-12-14       Impact factor: 3.240

6.  Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis.

Authors:  Rohan Chaminda Siriwardana; Madunil Anuk Niriella; Anuradha Supun Dassanayake; Chandika Anuradha Habarakada Liyanage; Angappulige Upasena; Chandra Sirigampala; Hithanadura Janaka de Silva
Journal:  BMC Gastroenterol       Date:  2015-08-04       Impact factor: 3.067

7.  Liver Abscess Formation Following Transarterial Chemoembolization: Clinical Features, Risk Factors, Bacteria Spectrum, and Percutaneous Catheter Drainage.

Authors:  Wei-Fu Lv; Dong Lu; Yu-Sheng He; Jing-Kun Xiao; Chun-Ze Zhou; De-Lei Cheng
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

8.  Jianpi-Huayu Formula Inhibits Development of Hepatocellular Carcinoma by Regulating Expression of miR-602, Which Targets the RASSF1A Gene.

Authors:  Yajing Huang; Cheng Zhou; Huihong Wen; Yongxu Chen; Yingjie Xie; Xiaohe Lan; Juze Lin; Xuhui Huang; Yousheng Mo; Cong Yang; Qi Wang; Changjun Wang
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

9.  Bloodstream Infection and Its Clinical Characteristics and Relevant Factors Associated with Interventional Therapy in a Large Tertiary Hospital: A Six Years Surveillance Study.

Authors:  Yanling Bai; Zhigang Zheng; Mingmei Du; Hongwu Yao; Yunxi Liu; Jijiang Suo
Journal:  Biomed Res Int       Date:  2019-10-21       Impact factor: 3.411

Review 10.  Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges.

Authors:  Hsuan Yeh; Chung-Cheng Chiang; Tzung-Hai Yen
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.